NCT03054142 China Collaborative Study on Epidemiology of Acute Kidney Injury
| NCT ID | NCT03054142 |
| Status | Recruiting |
| Phase | — |
| Sponsor | XinLing Liang |
| Condition | Acute Kidney Injury |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000,000 participants |
| Start Date | 2017-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000,000 participants in total. It began in 2017-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute kidney injury (AKI) is a common clinical syndrome, especially patients in the hospital. AKI has become a huge medical burden in China. Little information is available about this disease burden in our country. The investigators aimed to evaluate the burden of AKI and to analyze the related risk factors.
Eligibility Criteria
Inclusion Criteria: * The patients diagnosed on the basis of changes in serum creatinine according to the criteria of 2012 Kidney Disease Improving Global Outcomes(KDIGO) Exclusion Criteria: * Serum creatinine record less than two times during hospitalization * Patients being diagnosed with End-stage kidney disease (chronic kidney disease stage 5) * Nephrectomy * Kidney transplantation * Peak serum creatinine of less than 53µ mol/L * Serum creatinine decrease after amputation
Contact & Investigator
Liang Xinling, M.D.,Ph.D
PRINCIPAL INVESTIGATOR
Nephrology Dept,Guangdong General Hospital
Frequently Asked Questions
Who can join the NCT03054142 clinical trial?
This trial is open to participants of all sexes, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03054142 currently recruiting?
Yes, NCT03054142 is actively recruiting participants. Contact the research team at xinlingliang@139.com for enrollment information.
Where is the NCT03054142 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT03054142 clinical trial?
NCT03054142 is sponsored by XinLing Liang. The principal investigator is Liang Xinling, M.D.,Ph.D at Nephrology Dept,Guangdong General Hospital. The trial plans to enroll 1,000,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.